SCHEMBL1662956

SCHEMBL1662956

CNC(=O)Cn1cc(N)cn1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
MAP4K1 Q92918 1/20 0.41
PDK2 Q15119 4/20 0.41
MAPT P10636 3/20 0.41
MAP4K4 O95819 1/20 0.40
LMNA P02545 1/20 0.39
BTK Q06187 2/20 0.39
KDR P35968 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
HIF1A Q16665 1/20 0.38
PLK1 P53350 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALOX5AP P20292 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28599036 0.85 PDK2 (0.45) PDK2MAPTLMNABTKL3MBTL1
SCHEMBL16812317 0.81 NPC1 (0.43) MAPTLMNAL3MBTL1ALDH1A1PKM
SCHEMBL15058580 0.81 PDK2 (0.45) PDK2MAPTALDH1A1MEN1KMT2A
SCHEMBL13739798 0.81 MEN1 (0.42) MAPTLMNAL3MBTL1ALDH1A1PKM
SCHEMBL10084730 0.80 ALPI (0.51) CCNCCDK8PDK2MAPTLMNA
SCHEMBL673074 0.79 MAPT (0.42) PDK2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL1703493 0.79 MAPT (0.42) PDK2MAPTLMNAL3MBTL1ALDH1A1
SCHEMBL23011679 0.79 CCNC (0.43) CCNCCDK8MAP4K1PDK2MAPT
SCHEMBL17207643 0.79 TAS2R8 (0.44) CCNCCDK8PDK2MAPTMAP4K4
SCHEMBL17605717 0.79 ALDH1A1 (0.47) CCNCCDK8PDK2MAPTMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4656249-A2 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2025-12-03 EP disclosed
EP-3478687-B1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR DAEWOONG PHARMACEUTICAL CO LTD (KR) 2024-03-20 EP disclosed
CN-114292274-B Pyrrolo [2,3-d ] pyrimidine derivatives as JAK kinase inhibitors, and preparation method and application thereof 中国药科大学 2023-12-19 CN disclosed
US-20230039917-A1 EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2023-02-09 US disclosed
CN-110330484-B Substituted phenyl pyrimidine derivative as JAK kinase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application 中国药科大学 2022-08-26 CN disclosed
CN-114292274-A Pyrrolo [2,3-d ] pyrimidine derivatives as JAK kinase inhibitors, and preparation method and application thereof 中国药科大学 2022-04-08 CN disclosed
EP-3950691-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2022-02-09 EP disclosed
CN-109311896-B Pyrazolopyrimidine derivatives as kinase inhibitors 株式会社大熊制药 2021-08-24 CN disclosed
CN-113135920-A Pyrazolopyrimidine derivatives as kinase inhibitors 株式会社大熊制药 2021-07-20 CN disclosed
US-10961247-B2 Pyrazolopyrimidine derivatives as kinase inhibitor DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-03-30 US disclosed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 US disclosed
WO-2013014162-A1 HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2013-01-31 WO disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
CN-102666545-A Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors CELLZOME LTD 2012-09-12 CN disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 EP disclosed
CN-102498110-A 2- (LH-pyrazol-4-ylamino) -pyrimidine as kinase inhibitors ABBOTT LAB 2012-06-13 CN disclosed
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 EP disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 WO disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 US disclosed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB CCNC 341/4885CDK8 98/4885MAP4K1 147/4885
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 CCNC 991/4885CDK8 359/4885MAP4K1 246/4885
US-20230039917-A1 EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION BMI1, MLLT1, SUZ12 CCNC 3364/4885CDK8 1403/4885MAP4K1 1153/4885
US-10961247-B2 Pyrazolopyrimidine derivatives as kinase inhibitor MAP3K5, MAP3K2, MAPKAPK5 CCNC 1682/4885CDK8 285/4885MAP4K1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.